Serologic test for therapy control of HPV16 positive carcinoma
AssigneeAbviris Deutschland GmbH
InventorRalf Hilfrich
Life of this patent
Estimating the term…
Abstract
A method for therapy control of HPV16 positive carcinoma, an antibody for use in the corresponding diagnostic method as well as a test for performing the method. In particular, a serologic method for monitoring the development of the amount of antibodies in samples, which were taken from a patient before and after the treatment of a HPV16 positive carcinoma over a predetermined period of time. In addition, an immunologic test in the form of a kit, with which the method can be performed.
Claims13
A method for continued treatment of HPV16-positive carcinoma in a patient, the method comprising:
- (a) contacting a sample from the patient with an HPV16-positive carcinoma, said patient having been administered an anti-cancer therapy, with a plurality of antigens comprising a conformational epitope of HPV16 L1 capsid or capsomer, wherein said epitope is not present in monomeric and/or denatured HPV16 L1, under conditions at which antibodies present in the sample can bind to the antigens;
- (b) detecting antibody levels in the sample that bind to the antigens;
- (c) comparing the antibody levels to a reference level of antibodies, wherein the reference level of antibodies is from a sample taken from the patient prior to the anti-cancer therapy, wherein a reduction in the antibody levels is indicative the anti-cancer therapy in the patient is working, and wherein an increase in the antibody levels is indicative the anti-cancer therapy in the patient is not working;
- and
- (d) administering an additional anti-cancer therapy targeting HPV16-positive carcinoma in the patient, wherein the patient has an increase in the antibody levels compared to the reference level of antibodies.
A method for continued treatment of HPV16-positive carcinoma in a patient, the method comprising:
- i) mixing a sample of the patient with a plurality of antigens, said patient having been administered an anti-cancer therapy, wherein the antigens present HPV16 L1 capsid or capsomer structures, which have HPV16 L1 conformational epitopes not present in monomeric and/or denatured HPV16 L1, under conditions at which antibodies present in the sample can bind to the HPV16 L1 antigens,
- ii) contacting the mixture of step i) with labeled antibodies, which specifically bind to the conformational epitopes of the HPV16 L1 capsid or capsomer structure presenting antigens,
- iii) quantifying a level of the labeled antibodies and/or the antibodies of the sample, which have bound to the HPV16 L1 capsid or capsomer structure presenting antigens, respectively,
- iv) repeating steps i) to iii) one or more times with samples taken from the same patient in predetermined time intervals so that a trend of the level of antibodies that bind to the HPV16 L1 capsid or capsomer structure presenting antigens in the patient is tracked based on the samples over a predetermined period of time,
- v) determining the level of antibodies that bind to the HPV16 L1 capsid or capsomer structure presenting antigens in the samples,
- vi) comparing the level of antibodies determined in step v) with a reference level of antibodies, wherein the reference level of antibodies is from a sample taken from the patient prior to the anti-cancer therapy, wherein a decrease of the level of antibodies that bind over the predetermined period of time indicates the therapy is working, and wherein an increase in the level of antibodies that bind over the predetermined period of time indicates a reoccurrence of the HPV16-positive carcinoma, and
- vii) administering an additional anti-cancer therapy targeting HPV16-positive carcinoma in the patient, wherein the patient has an increase in the antibody levels compared to the reference level of antibodies.
Dependencies are inferred from the claim text.